These three stocks have already made a ton of millionaires, and they're probably going to make even more! So, Is it too late to add them to the portfolio?1.Constellation Software $Constellation Software, Inc.(CNSWF)$ is a powerhouse in acquiring leading software and services in the market. Their revenue has skyrocketed to $8 billion in 2023. With a strategy that combines organic growth and acquisitions, they've transformed into an international professional solutions provider. From 2007 to 2023, Constellation's stock price has seen an equally impressive transformation. Shares have soared from around $23 to the current $3,720, an increase of more than 16,000%. Obviously, many millionaires have been born.2.Shopify

AI stocks are stealing the spotlight from other emerging technologies, including quantum computing stocks. But don't worry, the explosion of quantum computing stocks in the US market is just a matter of time. According to BCC Research, this market is expected to grow at a whopping 48.1% CAGR from 2022 to 2028, reaching a whopping $6.5 billion!Here are three quantum computing stocks in the US market that combine stability with upside potential:1.IBM $IBM(IBM)$ is a pioneer in the quantum computing space. IBM Quantum is a world leader in building quantum hardware and plays a crucial role in commercializing this technology. Their goal? To effectively scale quantum computing to solve complex problems, reduce error rates, and develop industry-specific a

The bull market in the US stock market is essentially a bull market for these seven giants of tech with huge market caps. But the biggest investors in the US, those ginormous fund management companies, can't pile on the "Magnificent Seven" because they're bound by the rules of "diversification".However, these funds are willing to ditch their "diversification" status and pump up their holdings in the "Magnificent Seven", unleashing a fresh wave of investment funds flooding into these behemoth stocks. $HSBC Holdings PLC(HSBC)$ did some digging and found that almost every US fund manager- those with assets under management (AUM) of more than $1.9 trillion - underweights the "Magnificent Seven". Specifically, while the "Magnificent Seven" -

Shares of three biotech stocks, $Viking Therapeutics(VKTX)$ $Skye Bioscience Inc.(SKYE)$ $Janux Therapeutics, Inc.(JANX)$, have surged at least 269% so far this year. Do they have room to rise?1.Viking Therapeutics Since $Novo-Nordisk A/S(NVO)$ and $Eli Lilly(LLY)$ launched their own weight-loss treatments, both stocks have surged. VKTX is working on a GLP-1 therapeutic oral solution called VK2735. In Phase II trials, VK2735 performed even better than NVO's Wegovy or LLY's Zepbound.VKTX shares are up 269% year-to-date and could rise even higher as VK2735 advances in late-stage tri

On Monday, all three major US stock indices gave up their intraday gains and closed in the red. The $S&P 500(.SPX)$ fell 1.2% and below 5,100 points, marking a 2.6% decline over two trading sessions - the steepest drop in more than a year.Additionally, the $DJIA(.DJI)$ dipped 0.7%, and the $NASDAQ(.IXIC)$ tumbled 1.8%, with large-cap tech stocks taking the lead in the sell-off. $Microsoft(MSFT)$ $Apple(AAPL)$ and $NVIDIA Corp(NVDA)$ were among the top losers in the interest rate-sensitive tech sector.Almost all the stocks in the

图片 $Goldman Sachs(GS)$ is taking some profits out of soaring tech stocks and redirecting them towards lower-cost companies. A recent analysis shows that the combined market value of the "Magnificent Seven" has exceeded $13 trillion.Alexandra Wilson-Elizondo, co-chief investment officer of Goldman Sachs Multi-Asset Solutions, said the firm believes tech stocks will be under pressure, and is more optimistic about areas like energy and Japanese stocks. In her view, the US economy is heading towards a soft landing, but there are plenty of risks that could change that trajectory.She added:We love taking profits in tech and moving them to other sectors. In tech, the risk-reward ratio is tipping towards the downside. While we still believe in being long st

图片In the past 12 months, the stock price of $Eli Lilly(LLY)$ has skyrocketed to triple digits, and the most significant driving force behind this surge is weight loss drugs. The weight loss drug market is poised to become a colossal $100 billion industry, and Eli Lilly's two weight loss drugs, Mounjaro and Zepbound, are both expected to become long-term blockbusters.In the weight loss drug market, Eli Lilly and $Novo-Nordisk A/S(NVO)$ still hold the lion's share. But here's the kicker: Eli Lilly is poised to continue dominating this market in the future.First, Mounjaro was approved to treat type 2 diabetes, but doctors often prescribe it as a weight loss drug, and it brought in more than $5 billion in reven

图片It looks like Chinese stocks are on the verge of a rebound, and analysts are finding more reasons to be bullish on them! At the end of March, investment analysts from $Citigroup(C)$ , $Morgan Stanley(MS)$ , and $Bank of America(BAC)$ upgraded their ratings on at least three Chinese stocks: $Tencent Music(TME)$ $Kingsoft Cloud Holdings Ltd(KC)$ $21vianet(VNET)$.Chris Brightman, the chief investment officer of Research Affiliates LLC, a quantitative fund under Pacific Investment Management Co., said that as valuations have become cheaper, we're

图片While $Madrigal Pharmaceuticals(MDGL)$ 's stock price has only gone up about 5% in the past year, things are looking up for this mid-cap biotech company. With its latest medicine approval, Madrigal has successfully entered an underserved market and is ready to start reporting sales for the first time.On March 14th, the FDA gave the green light to Madrigal's Rezdiffra therapy, the first drug approved to treat metabolic dysfunction-associated steatohepatitis (MASH), which used to be known as non-alcoholic steatohepatitis (NASH).This drug got approved on an accelerated basis, so regulators are obviously confident in its effectiveness. With about 1.5 million Americans suffering from MASH, and the company's approved therapy able to treat about 315,00

图片Now, $Novo-Nordisk A/S(NVO)$ and $Eli Lilly(LLY)$ are dominating the weight loss market, but a rising biotech star might just give them a run for their money. $Viking Therapeutics(VKTX)$ is a small but mighty biotech company, focused on developing treatments for metabolic and endocrine disorders. Many other pharma giants have tried and failed to break into this booming market, but Viking seems to be on the right track.Weeks ago, Viking announced positive results from the Phase II trial of its GLP-1 and GIP dual agonist, VK2735. The hype surrounding this obesity drug candidate has sent Viking's stock soaring!With this Phase II success, Viking has a few clear optio

图片In the past few years, $Novo-Nordisk A/S(NVO)$ has been on a roll in the capital markets, with its diabetes drug Ozempic and weight-loss drug Wegovy igniting a frenzy. Its stock price has skyrocketed 270% in the past three years. But now, the weight-loss stock is about to get even hotter with the arrival of its "third fire" - the oral weight-loss drug amycretin.Recent trial results for amycretin released by Novo Nordisk show that this experimental drug is even more effective than Ozempic and Wegovy in terms of weight loss. As a result, the company is considering skipping straight to phase three trials.If this plan pans out, it'll speed up the development and launch of amycretin. But let's be realistic - even if it does work, this weight-loss drug

图片Under the double pressure of falling COVID-19 sales and the patent cliff, $Pfizer(PFE)$ 's stock price has plunged more than 50% from its peak in late 2021 and over 30% in the past 12 months. Sales and profits have also taken a nosedive.Still, there are five reasons to buy the drugmaker right now.1.COVID-19 Has Hit BottomThe recent decline in Pfizer's stock price can largely be attributed to the decreasing demand for COVID-19 products, such as the Comirnaty vaccine and Paxlovid oral drug. Fortunately, the company's COVID-19 sales are expected to have bottomed out, greatly reducing inventory impairments and year-over-year performance pressure. Even better, the company expects to launch a combination COVID-flu vaccine in 2025, which could boost sal

The FDA has approved the first-ever treatment for a common and potentially fatal liver disease that affects millions of people worldwide.This FDA decision means that $Madrigal Pharmaceuticals(MDGL)$ has scored a major victory in a disease area where several big companies have failed or are still struggling to get in. Following the approval, Madrigal's stock price jumped over 20%.$Novo-Nordisk A/S(NVO)$ and $Eli Lilly(LLY)$ are testing their heavyweight weight-loss injections to treat nonalcoholic steatohepatitis (NASH).Madrigal's drug, to be marketed as Rezdiffra, is specifically designed for NASH patients with moderate to severe liver scarring. The FDA says this t

图片Here are three solid reasons why investing in $CVS Health(CVS)$ and holding it for the long term is a great move:1.CVS Health is bigger than you think!You might be familiar with CVS Health's chain of pharmacies with over 9,000 stores, but there's more to it! Last year, the company reported a total adjusted operating profit of $17.5 billion,with just $6 billion coming from the pharmacy and consumer health segment. Did you know CVS Health also owns Aetna, one of the largest health insurance companies in the US, with over 25.7 million members? Operating profit in the company's health and benefits division fell 12% last year, but it was still $5.6 billion. Finally, the company's healthcare services segment, which includes the pharmacy benefit managem

图片One great way to invest in healthcare is to target medical device manufacturers. These devices help doctors perform surgeries, aid patients in recovery, and assist people in managing chronic conditions like hypertension and diabetes.But it's not a hotbed of investment opportunities. Since 2021, the $iShares Dow Jones U.S. Medical D(IHI)$ has only gone up 6%, while the $S&P 500(.SPX)$ has surged over 36%. But because many investors have overlooked medical device stocks, there are some attractive buying opportunities. $Medtronic PLC(MDT)$ and $DexCom(DXCM)$ are key players in this space. Given their solid financials an

图片Shares of biopharmaceutical giant $Pfizer(PFE)$ will rise about 75% over the next few quarters and surpass $45, according to Cantor Fitzgerald, a analyst from Louise Chen, based on his bullish outlook for the company's transformation. That's a shift in revenue from reliance on COVID-19 drugs like Paxlovid and Comirnaty to cancer treatments.With the oncology pipeline starting to take off, is Pfizer a good buy at around $26 a share?The new strategy is going very well. Pfizer's strategic plan to become a leader in the cancer drug market is no joke.The company currently has 17 cancer programs in Phase 3 clinical trials or awaiting regulatory approval from FDA. This year, two product candidates are expected to be approved for market, two more research

图片The cleantech market is a very broad and large field, encompassing renewable energy sources like wind and solar, battery technology for electric cars and large-scale energy storage systems, agricultural technology, water and air purification systems, building environmental technology, carbon capture, and green hydrogen, to name a few. As a result, picking stocks in the US clean energy market can be a real headache. But there's an easier way - investing in clean energy exchange-traded funds (ETFs). Compared to investing in individual stocks, clean energy ETFs can significantly reduce the risk of stock selection and achieve diversification in one fell swoop. Here are the top 5 largest US clean energy ETFs in 2024 based on total assets (data as of February 29, 2024):1.iShares Global Clean E

图片While stocks have been on a roll in the past three years, many speculative and unprofitable companies have struggled, and investors have moved on. One such company is $Editas Medicine(EDIT)$, a clinical-stage genetic editing biotech.But many Wall Street analysts are bullish on this stock. The average target price for Editas is $15.64, which means there′ s about 55% upside from the stock's $10.06. Can the company hit that target next year? Stay tuned!Multiple Catalysts on the HorizonLast year was an exciting one for genetic editing. Editas released encouraging data from its ongoing trials for EDIT-301, a potential drug for treating transfusion-dependent beta-thalassemia (TDT) and sickle cell disease (SCD), two rare blood disorders. And the safety

Recently, the Magnificent Seven( $Apple(AAPL)$ $Microsoft(MSFT)$ $Alphabet(GOOG)$ $Alphabet(GOOGL)$ $Amazon.com(AMZN)$ $Meta Platforms, Inc.(META)$ $Tesla Motors(TSLA)$ $NVIDIA Corp(NVDA)$ )stocks have been attracting a lot of attention, and their share prices have been skyrocketing since the beginning of 2023. Investors appreciate their growth prospects. But that doesn't mean there aren't other places to invest.Look at

图片Last week, $Editas Medicine(EDIT)$, a clinical-stage genome-editing company, made two major announcements that sent its stock up 41.6% and remained up 34.8% for the week as of Friday's close. The two big benefits are the gene-editing company's latest quarterly report and the latest progress of the trial.Last Wednesday, Editas Medicine released its fourth-quarter report, which was better than investors' expectations. Specifically, the company reported revenue of $60 million and a loss of $0.23 per share, while analysts expected revenue of $7.94 million and a loss of $0.54 per share.However, compared to its revenue and earnings, Editas' cash position is even more noteworthy. As of December 31, 2023, the company had $427.1 million in cash, cash equ